Smarter Commercialization Investment for First Launch Biopharma

Home / Intelligence / White Papers / Smarter Commercialization Investment for First Launch Biopharma

With more momentum than ever to bring innovative medicines to market, there is increased pressure on emerging companies to get the launch right. The industry has seen record-breaking funding for therapies in recent years, and many have been commercialized by emerging biopharma companies launching for the first time. For many of these emerging biopharma companies, optimizing commercial launch spend is a critical consideration pre- and post-launch, and with limited funds it can be easy to misjudge the timing of key investments or underfund crucial capabilities.

To help guide commercialization decisions, in this paper Trinity Life Sciences explores pre-launch and first year commercial spend, specifically, U.S. Selling, General and Administrative (SG&A) costs; expected revenue; and actual sales. Leveraging our experience and industry network of experts, we uncover what works, and what doesn’t, so emerging companies can leverage these insights to prepare for their critical launches. What works for one type of product or market doesn’t necessarily work for another, and our analysis highlights the effectiveness of various launch investments across three market cohorts: Specialty, Rare Disease (non-Oncology), and Rare Oncology.

The study reveals several themes (by type of market) that should be considered as part of an emerging company’s launch spend strategy to achieve commercialization success. Most importantly, more spend isn’t always better; what matters is where and when you invest.

Complete the form below to access the full white paper

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email

Related Intelligence